| Literature DB >> 35991169 |
Yuhui Su1,2, Yafeng Song3.
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive fatal muscular disease. Gene therapy, cell therapy, and drug therapy are currently the most widely used treatments for DMD. However, many experiments on animals and humans suggested that appropriate exercise could improve the effectiveness of such precision medicine treatment, thereby improving patient's muscle quality and function. Due to the striated muscle damage of DMD individuals, there are still many debates about whether DMD animals or patients can exercise, how to exercise, when to exercise best, and how to exercise effectively. The purpose of this review is to summarize and investigate the scientific basis and efficacy of exercise as an adjuvant therapy for DMD gene therapy, cell therapy and drug therapy, as well as to present the theoretical framework and optional strategies of "exercise + X″″ combination therapy.Entities:
Keywords: DMD; combined therapy; duchenne muscular dystrophy; exercise; mdx
Year: 2022 PMID: 35991169 PMCID: PMC9389311 DOI: 10.3389/fphys.2022.947749
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.755
A possible mechanism of action between benificial and harmful exercise.
| Benificial exercise | Harmful exercise | |
|---|---|---|
| muscle regeneration | increase the expression of homologous protein utrophin | telomeres shorten in muscle cells |
| promote muscle regeneration, increase muscle strength and bone mass | increase cell apoptosis and the amount of damaged necrotic tissue | |
| oxidative stress | reduce oxidative stress and improve energy metabolism | increase the expression of fast muscle fiber and upregulate oxidative stress |
| muscle fatiguability | maintain the excitability of muscle cells, activate the calcineurin pathway, and reduce muscle fatiguability | activate Ca2+ dependent muscle degradation and increase muscle fatiguability |
| • inflammatory response | increase the level of serum adiponectin which can sensitize insulin, burn fat, and ameliorate inflammatory disorders | upregulate ECM proteins involved in innate immunity pathways, downstream receptors and signaling molecules, and increase macrophage infiltration |
Efficacy comparison of major DMD therapies.
| Therapy | Object | Method | Result | References |
|---|---|---|---|---|
| Dystrophin gene therapy | DMD boy | The AAV2.5 vector was injected into one arm’s biceps brachii muscle | All patients had recombinant AAV genomes but no cellular immune response. AAV2. 5, the carrier is non-hazardous and well tolerated |
|
| micro-dystrophin gene therapy | GRMD dog | The rAAV2/8-micro-dystrophin expression vector was injected intravenously | The symptoms of muscular dystrophy were relieved, and there was no toxicity or adverse immune effects from rAAV administration |
|
| micro-dystrophin | mdx/mTR (G2) mouse | Systemic injection of rAAV6-micro- dystrophin | Mice’s muscle force was increased |
|
| gene therapy | ||||
| Utrophin gene therapy | mdx | AAV-Utro intravenous injection | Histological and physiological lesions of muscular dystrophy could be avoided in mouse and large dog models |
|
| mouse | ||||
| GRMD dog | ||||
| Autologous cell therapy | mdx/SCID mouse | Dystrophin was transfected with a monoclonal antibody and implanted into a mouse’s muscle or artery | The elastic properties of 80% muscle fibers were restored to wild-type performance, which was more fatigue resistant |
|
| Exosome mediated cell therapy | mdx | Cardiac injection of cardiac progenitor cells (CDCs) | CDCs and their exosomes temporarily restored the expression of partial full-length dystrophin in mdx mice |
|
| mouse | ||||
| Prednisone | DMD boy | Prednisone 0.75 mg/kg per day was administered on a 10 days on/10 days off basis | When compared to historical controls, prednisone 10 on/10 off has fewer side effects and extends the ambulant phase by 1 year |
|
| Pharmaco therapy | ||||
| Prednisone Pharmaco therapy | DMD boy | two prednisone schedules (daily 0.75 mg/kg/day and weekend 10 mg/kg/wk), 12 months | Over a 12-month period, weekend prednisone dosing was as safe and effective as daily prednisone in preserving muscle strength and preventing body mass index increases in boys with DMD. |
|
| Idebenone | mdx | 4 weeks to 10 months old, 200 mg/kg body weight | It improved voluntary running ability, prevented heart failure, reduced cardiac inflammation and fibrosis, and improved cardiac diastolic dysfunction |
|
| Pharmaco therapy | mouse | |||
| Laminin-111pharmaco therapy | GRMD dog | The protein Mslam-111 was injected into the craniotibial muscle | It increased muscle fiber regeneration and repair, enhanced muscle strength and reduced muscle fibrosis |
|
| sActRIIB-Fcpharmaco therapy | mdx | Soluble activin receptor sactriib FC was injected to block myostatin | Muscle mass increased |
|
| mouse | ||||
| Resveratrol traditional Chinese medicine therapy | mdx | 4 weeks of age,5 mg/kg bw/day and 15 weeks of treatment | The expression of immune cell markers CD86 and CD163 decreased, and muscle necrosis was alleviated. |
|
| mouse | ||||
| Voluntary wheel running | mdx | 8 weeks of voluntary wheel running (3–4 days a week) | Prolonged skeletal muscle suspension time and increased dystrophin expression had a positive effect on skeletal muscle and myocardial function |
|
| mouse | ||||
| Voluntary wheel running | mdx | 12 weeks of voluntary low resistance wheels | Central nucleus muscle fiber decreased, skeletal muscle contraction function improved and fatigue decreased, and there was no sign that exercise was harmful |
|
| mouse | ||||
| Voluntary wheel running | mdx | 7 weeks of voluntary wheel running | The oxidative capacity and autophagy markers of skeletal muscle was increased, and were even higher than in healthy mice |
|
| mouse | ||||
| Treadmill training | mdx | Running at a speed of 12 m/min for 30 min, twice a week, with a 48-h or 72-h interval (12 times in total) | Impaired muscle regeneration and the failure of endogenous anti-inflammatory signals exacerbate chronic inflammation and result in more severe muscle phenotypes |
|
| mouse | ||||
| Treadmill training | mdx | For 6 weeks, 5 days per week, use the treadmill to gradually increase the load | There was no significant improvement in diaphragm |
|
| mouse | ||||
| Treadmill training | mdx | 4 m/min or 8 m/min, three times a week, 30 min each time, for a total of 6 months | Improved muscle rigidity and strength, respiratory capacity and cardiac function; decreased the cross-sectional area of adipocytes |
|
| mouse | ||||
| Progressive swimming | Progressive swimming | Four times a week for a total of 4 weeks, 15 min per day in the first week, 20 min per day in the second week, and 30 min per day in the third and fourth weeks | The levels of lipid peroxidation in gastrocnemius, diaphragm, hippocampus and striatum were significantly decreased |
|
| micro-dystrophin | mdx | rAAV6:µDysH3 and rAAV6:µDys5 | Both rAAV have the same dose response to prevent muscle damage caused by repeated high-intensity exercise |
|
| exercise+ | mouse | Gene therapy + repeated high-intensity exercise | ||
| gene therapy | ||||
| A pair of AAVs exercise+ gene therapy | mdx | A pair of AAV vectors were injected into the caudal vein to express nNOS bound dystrophin gene | It improved histopathology, increased muscle strength and prevented eccentric contraction injury and muscle strength decline caused by chronic exercise |
|
| mouse | ||||
| mdx4cv | ||||
| mouse | ||||
| Exercise + | mdx mouse | Running at a speed of 12 m/min for 30 min, twice a week for 4–8 weeks. Pentoxifylline (50 mg/kg/day) was injected during exercise | The Ca2+channel activity in mdx mice treated with exercise + pentoxifylline was similar to that in wild-type mice |
|
| pentoxifylline |